Verification evidence is still being completed.
PDF / print export
Apogenix AG
Berlin, Germany
- Verified lead
- Dr. Thomas Hoeger
- Lead status
- STATUS: VERIFIED MARCH 2026
- Leadership verification
- Chief Executive Officer
- 2026 technical specialization
- Immunotherapy
- Review cycle
- May 2026
- Full address
- Im Neuenheimer Feld 584, 69120 Heidelberg, Germany
- Site coordinates
- Verification evidence is still being completed.
- Editorial review
- Memel Biotech editorial review
- Official leadership source
- Official Apogenix management board page confirming Dr. Thomas Hoeger as CEO.
- Editorial note
- Apogenix is published as an active Heidelberg therapeutics company with current management disclosure, a documented Heidelberg site, and a still-live immunotherapy company profile.
Immunotherapy
Clinical Stage
Apogenix is published as an active Heidelberg therapeutics company with current management disclosure, a documented Heidelberg site, and a still-live immunotherapy company profile.
Review coverage
Leadership
Facility
Certifications
Capabilities
Partners
Sources
Quality
Editorial verificationMemel Biotech directory review sign-off
Report generated05 Jun 2026, 01:06
Company profile · Berlin, Germany
Apogenix AG
Immunotherapy · Clinical Research
Verified 14 Mar 2026 · 3 sources
Clinical
Apogenix AG runs tnfsf ligand hub, fusion proteins, and solid tumor research in Berlin, Germany.
Contact & location
- Website
- apogenix.com
- Company page
- Lead
- Dr. Thomas Hoeger (verified ↗)
- Compliance
- Not yet on record
- Last reviewed
- 14 Mar 2026 (3mo ago)
- Scale
- Clinical Research
- Capabilities
- TNFSF Ligand Hub · Fusion Proteins · Solid Tumor Research
- Founded
- 2005
- Headcount
- 11-50
Clinical profileSTATUS: VERIFIED MARCH 2026
Dr. Thomas Hoeger
Chief Executive Officer
Full addressIm Neuenheimer Feld 584, 69120 Heidelberg, Germany
Site coordinatesVerification evidence is still being completed.
Review cycleMay 2026
Physical site source
Official Apogenix contact page identifying the Heidelberg site at Im Neuenheimer Feld 584.
Open sourceClinical Research
Berlin, Germany. Immunotherapy. Review completed on 14 Mar 2026.
PEI
Clinical Stage
Immunotherapy
Apogenix is published as an active Heidelberg therapeutics company with current management disclosure, a documented Heidelberg site, and a still-live immunotherapy company profile.
Editorial note
Apogenix is published as an active Heidelberg therapeutics company with current management disclosure, a documented Heidelberg site, and a still-live immunotherapy company profile.
FULL TRUST REVIEW COMPLETE
Shown only when all seven trust checks are fully mapped in the directory.
Current review cycleMarch 2026
Capabilities
Core capabilities
Primary declared technical activities and areas of operating focus.
TNFSF Ligand Hub
Fusion Proteins
Solid Tumor Research
Verification source dossier
Verification source dossier
Official source set used to support leadership, physical-site, certification, and watch-note evidence.
Infrastructure
Declared infrastructure
Protein Characterization Skids
Regulatory posture
Quality system coverage
GMP / GLP / ISO-13485 / FDA-Inspected are global quality-system standards. "Verified active" means the directory confirmed the certification is current; "Review in progress" means the cert status is currently being re-verified.
- GMP
- REVIEW IN PROGRESS 2026
- GLP
- REVIEW IN PROGRESS 2026
- ISO-13485
- REVIEW IN PROGRESS 2026
- FDA-Inspected
- REVIEW IN PROGRESS 2026
Verification history
Verification history
14 Mar 2026: Executive identity confirmed via official management disclosure.
14 Mar 2026: Full trust review completed.
FAQ
Frequently asked questions
- Where is Apogenix AG located?
- Apogenix AG operates from Im Neuenheimer Feld 584, 69120 Heidelberg, Germany, Berlin, Germany.
- Who runs Apogenix AG?
- Apogenix AG is led by Dr. Thomas Hoeger, Chief Executive Officer. Verified 14 Mar 2026.
- What does Apogenix AG do?
- Apogenix AG runs tnfsf ligand hub, fusion proteins, and solid tumor research in Berlin, Germany. Core capabilities: TNFSF Ligand Hub, Fusion Proteins, Solid Tumor Research.
Editorial context
Related technical briefs
Briefs that name Berlin as a covered market or city.